Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans

A.D. Paulussen, K. Lavrijsen, H. Bohets, J. Hendrickx, P. Verhasselt, W. Luyten, F. Konings, M. Armstrong

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans.

Paulussen A, Lavrijsen K, Bohets H, Hendrickx J, Verhasselt P, Luyten W, Konings F, Armstrong M.

Department of Pharmacogenomics, Janssen Research Foundation, Janssen Pharmaceutica, Beerse, Belgium.

Cytochrome P450 3A subfamily members (CYP3A) are the most abundant liver cytochrome P450 forms, responsible for the biotransformation of over 50% of all drugs. The expression and activity of isoforms CYP3A4 and CYP3A5 show wide inter-individual variation, influencing both drug response and disease susceptibility. The molecular basis for this variation has never been defined. In this study, we used midazolam to characterize CYP3A5 phenotype in a panel of liver samples. A clear bimodality in metabolism was observed. Analysis of the 5' flanking region of the CYP3A5 gene identified two linked polymorphisms, T-369G and A-45G, located in transcriptional regulatory elements which are associated with increased expression and activity of the gene. A polymerase chain reaction based detection assay is described facilitating
Original languageEnglish
Pages (from-to)415-424
JournalPharmacogenetics
Volume10
Issue number5
DOIs
Publication statusPublished - 1 Jan 2000

Cite this